- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 54-68 of
362 results
2009 Exhibit: Ex 2009 NIH clinicaltrialsgov, Eli Lilly, A Study of Tirzepatide 6262017
Document
IPR2025-01346, No. 2009 Exhibit - Ex 2009 NIH clinicaltrialsgov, Eli Lilly, A Study of Tirzepatide 6262017 (P.T.A.B. Oct. 14, 2025)
|
|
Cite Document
2038 Exhibit: Ex 2038 Buntz Drug Discovery Dev 10162023
Document
IPR2025-01346, No. 2038 Exhibit - Ex 2038 Buntz Drug Discovery Dev 10162023 (P.T.A.B. Oct. 14, 2025)
|
|
Cite Document
2014 Exhibit: Ex 2014 Frias et al Lancet 2018
Document
IPR2025-01346, No. 2014 Exhibit - Ex 2014 Frias et al Lancet 2018 (P.T.A.B. Oct. 14, 2025)
|
|
Cite Document
2016 Exhibit: Ex 2016 Helfand Fierce Pharma 1082018
Document
IPR2025-01346, No. 2016 Exhibit - Ex 2016 Helfand Fierce Pharma 1082018 (P.T.A.B. Oct. 14, 2025)
|
|
Cite Document
2004 Exhibit: Ex 2004 Beauroyre Abacum 6252025
Document
IPR2025-01346, No. 2004 Exhibit - Ex 2004 Beauroyre Abacum 6252025 (P.T.A.B. Oct. 14, 2025)
|
|
Cite Document
2023 Exhibit: Ex 2023 Jastreboff et al NEJM 2022
Document
IPR2025-01346, No. 2023 Exhibit - Ex 2023 Jastreboff et al NEJM 2022 (P.T.A.B. Oct. 14, 2025)
|
|
Cite Document
2033 Exhibit: Ex 2033 Mullard Nature Revs Drug Discovery 5202022
Document
IPR2025-01346, No. 2033 Exhibit - Ex 2033 Mullard Nature Revs Drug Discovery 5202022 (P.T.A.B. Oct. 14, 2025)
|
|
Cite Document
2013 Exhibit: Ex 2013 Eli Lilly Press Release 1042018
Document
IPR2025-01346, No. 2013 Exhibit - Ex 2013 Eli Lilly Press Release 1042018 (P.T.A.B. Oct. 14, 2025)
|
|
Cite Document
2003 Exhibit: Ex 2003 PhRMA Research Development Policy Framework Sept 2024
Document
IPR2025-01346, No. 2003 Exhibit - Ex 2003 PhRMA Research Development Policy Framework Sept 2024 (P.T.A.B. Oct. 14, 2025)
|
|
Cite Document
2019 Exhibit: Ex 2019 Eli Lilly Press Release 6252021
Document
IPR2025-01346, No. 2019 Exhibit - Ex 2019 Eli Lilly Press Release 6252021 (P.T.A.B. Oct. 14, 2025)
|
|
Cite Document
2037 Exhibit: Ex 2037 Doctors Business Network 4282025
Document
IPR2025-01346, No. 2037 Exhibit - Ex 2037 Doctors Business Network 4282025 (P.T.A.B. Oct. 14, 2025)
|
|
Cite Document
2034 Exhibit: Ex 2034 Biochem PEG 5202022
Document
IPR2025-01346, No. 2034 Exhibit - Ex 2034 Biochem PEG 5202022 (P.T.A.B. Oct. 14, 2025)
|
|
Cite Document
2035 Exhibit: Ex 2035 Wang Drug Design Dev Therapy 2022
Document
IPR2025-01346, No. 2035 Exhibit - Ex 2035 Wang Drug Design Dev Therapy 2022 (P.T.A.B. Oct. 14, 2025)
|
|
Cite Document
2088 Exhibit: Ex 2088 Search Results from USP 9474780 File History
Document
IPR2025-01024, No. 2088 Exhibit - Ex 2088 Search Results from USP 9474780 File History (P.T.A.B. Oct. 2, 2025)
|
|
Cite Document
2081 Exhibit: Ex 2081 Eli Lilly Co 10 K FY 2024
Document
IPR2025-01024, No. 2081 Exhibit - Ex 2081 Eli Lilly Co 10 K FY 2024 (P.T.A.B. Sep. 22, 2025)
|
|
Cite Document
